Evaluation of Heart Failure Treatment Guided by N-termina... | NCT00391846

NCT00391846

Status Module

Sponsor/Collaborators Module

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Guided by NT-proBNP	Other	Treatment guided by clinical symptoms and signs + NTproBNP	Drug: Captopril Drug: Enalapril Drug: Lisinopril Drug: Ramipril Drug: Trandolapril Drug: Bisoprolol Drug: Carvedilol Drug: Metoprolol succinate Drug: Candesartan Drug: Valsartan Drug: Eplerenone Drug: Spironolactone Drug: Diuretics Drug: HF treatment according to Swedish guidelines Procedure: Blood samples Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
Not Guided by NT-proBNP	Other	Treatment guided by clinical symptoms and signs	Drug: Captopril Drug: Enalapril Drug: Lisinopril Drug: Ramipril Drug: Trandolapril Drug: Bisoprolol Drug: Carvedilol Drug: Metoprolol succinate Drug: Candesartan Drug: Valsartan Drug: Eplerenone Drug: Spironolactone Drug: Diuretics Drug: HF treatment according to Swedish guidelines Procedure: Blood samples Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

Name	Type	Description	Arm Group Labels	Other Names
Captopril	Drug		Guided by NT-proBNP Not Guided by NT-proBNP
Enalapril

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)	The non-parametric scale is constructed from 3 variables, modified after Cleland. Each patient receives a rank score from 1 to 246 (246-number of patients in the study). The lowest score receive patients who die (due to CV event), next patients still alive at end-of-study with the worst composite score, the best alive patients with 0 days in hospital and the largest improvement in the KCCQ (self-administered by patient symptom score, where the higher score reflect better health status). Scores will be summarized using non-parametric calculations. The mean of non-parametric scores is presented	9 months

Measure	Description	Time Frame
Number of CV Deaths	Number of deaths	9 months
Number of Days in Hospital for CV Reason	Each overnight stay is counted as one day. The lower the better

Eligibility Module

Contacts/Locations Module

Overall Officials

Name	Affiliation	Role
AstraZeneca Sweden Medical Director, MD	AstraZeneca	Study Director
Hans Persson, MD, PhD	Danderyd Hospital, Sweden	Principal Investigator
Bjorn Eriksson, MD	AstraZeneca	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Research Site		Alvesta			Sweden
Research Site

References Module

No data available

No data is available for this block.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
FG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

FG000127 subjectsOf the 127 randomised patients 8 were discontinued

FG001125 subjectsOf th 125 randomised patients 7 were discontinued

Type of Units Analyzed

Arm/Group Information

ID	Title	Description
BG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
BG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age Continuous

Mean

Full Range

Years

Title

Denominators

Categories

Title	Measurements
	BG00078(57 to 92) BG00177(51 to 94) BG00277(51 to 94)

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG00030 BG00142 BG002

Electrocardiogram (ECG), Abnormal/Normal

Number

Participants

Title

Denominators

Categories

Abnormal ECG

Title	Measurements
	BG000115 BG001113 BG002

Diastolic blood pressure

Mean

Standard Deviation

mmHg

Title

Denominators

Categories

Title	Measurements
	BG00073± 11 BG00175± 12 BG002

Pulse

Mean

Standard Deviation

Beats/minute

Title

Denominators

Categories

Title	Measurements
	BG00071± 14 BG00172± 14 BG002

Systolic blood pressure

Mean

Standard Deviation

mmHg

Title

Denominators

Categories

Title	Measurements
	BG000133± 21 BG001135± 22 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)

The non-parametric scale is constructed from 3 variables, modified after Cleland. Each patient receives a rank score from 1 to 246 (246-number of patients in the study). The lowest score receive patients who die (due to CV event), next patients still alive at end-of-study with the worst composite score, the best alive patients with 0 days in hospital and the largest improvement in the KCCQ (self-administered by patient symptom score, where the higher score reflect better health status). Scores will be summarized using non-parametric calculations. The mean of non-parametric scores is presented

In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.

Posted

Mean

Standard Deviation

Scores on a scale

9 months

ID	Title	Description
OG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
OG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Units	Counts
Participants	OG000123 OG001123

Title

Denominators

Categories

Title	Measurements
	OG000118.6± 558 OG001128.4± 558

Secondary

Number of CV Deaths

Number of deaths

In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.

Posted

Number

Participants

9 months

ID	Title	Description
OG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
OG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Units	Counts
Participants	OG000

Secondary

Number of Days in Hospital for CV Reason

Each overnight stay is counted as one day. The lower the better

In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.

Posted

Mean

Standard Deviation

Days in hospital

9 months

ID	Title	Description
OG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
OG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Units	Counts
Participants	OG000

Secondary

Changes in Heart Failure Symptoms

Changes from baseline in the symptom score subset (question 3, 5, 7 and 9) of KCCQ (swelling, fatigue, shortness of breath, shortness of breath night time). KCCQ is a self-administered by patient symptom score, where higher score reflect better health status. Scale scores are transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100. This mean that the KCCQ scale is from 0 to 100 with the higher value showing a better health status.

In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.

Posted

Mean

Standard Deviation

Categorial scale

9 months and baseline

ID	Title	Description
OG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
OG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Units	Counts
Participants

Secondary

Changes in NT-proBNP Values Over Time in All Patients

The 95% confidential interval (CI) is given as measure of dispersion

In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.

Posted

Geometric Mean

95% Confidence Interval

ng/L

9 months and baseline

ID	Title	Description
OG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
OG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Units	Counts
Participants	OG000

Secondary

Changes in Health-related Quality of Life

Change range -100 to 100. The higher the better.

In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.

Posted

Mean

Standard Error

KCCQ overall score

9 months and baseline

ID	Title	Description
OG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
OG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Units	Counts
Participants	OG000

Secondary

Total Number of Titration Steps in Prescribed Heart Failure Treatment

Each titration step in prescribed medication is counted as one step, either up or down. One step up indicates an increase of dose in prescribed medication and one step down indicates a decrease of dose in prescribed medication. The sum of steps is given as a score. Score is given for each arm as a total number of titration steps for all patients in arm.

In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.

Posted

Number

Titration steps

9 months

ID	Title	Description
OG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
OG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Units	Counts
Participants	OG000

Secondary

Discontinuations

Number of patients discontinued due to adverse events'

In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.

Posted

Number

Participants

9 months

ID	Title	Description
OG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP
OG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs

Units	Counts
Participants	OG000

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP			46	127	0	127
EG001	Not Guided by NT-proBNP	Chronic heart failure treatment guided by clinical symptoms and signs			41	125	0	125

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Acute Myocardial Infarction	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Anaemia	Blood and lymphatic system disorders	MedDRA 10.0	Systematic Assessment	EG0002 affected127 at risk EG0012 affected125 at risk
Angina Pectoris	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0002 affected127 at risk EG0011 affected125 at risk
Angina Unstable	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Aortic Aneurysm	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0012 affected125 at risk
Aortic Stenosis	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Artial Fibrillation	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0002 affected127 at risk EG0013 affected125 at risk
Atrioventricular Block Complete	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
B-Cell Lymphoma	Blood and lymphatic system disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Back Pain	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Bladder Neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Bleeding Varicose Vein	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Blood Electrolytes Abnormal	Injury, poisoning and procedural complications	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Blood Pressure Decreased	Injury, poisoning and procedural complications	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Bradycardia	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0011 affected125 at risk
Bronchitis	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0012 affected125 at risk
Calculus Ureathral	Renal and urinary disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Cardiac Failure	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG00012 affected127 at risk EG0017 affected125 at risk
Carotid Artery Stenosis	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Cerebral Infarction	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Cerebrovascular Accident	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0012 affected125 at risk
Chest Pain	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0012 affected125 at risk
Chronic Lymphocytic Leukaemia	Blood and lymphatic system disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Chronic Obstructive Pulmonary Disease	Respiratory, thoracic and mediastinal disorders	MedDRA 10.0	Systematic Assessment	EG0003 affected127 at risk EG0012 affected125 at risk
Concussion	Injury, poisoning and procedural complications	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Confusional State	Psychiatric disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Death	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Dehydration	Metabolism and nutrition disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Diarrhoea	Gastrointestinal disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0012 affected125 at risk
Diverticulitis	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Duodenal Ulcer Haemorrhage	Gastrointestinal disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Dyspepsia	Gastrointestinal disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA 10.0	Systematic Assessment	EG0003 affected127 at risk EG0012 affected125 at risk
Endocarditis	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Fatigue	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Femur Fracture	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Gastrointestinal Haemorrhage	Gastrointestinal disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Gastrointestinal Tract Adenoma	Gastrointestinal disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Haematemesis	Gastrointestinal disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Headache	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Heamorrhage	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Hepatic Failure	Renal and urinary disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Hip Fracture	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Hyperkalaemia	Metabolism and nutrition disorders	MedDRA 10.0	Systematic Assessment	EG0002 affected127 at risk EG0011 affected125 at risk
Hypertension	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Intermittent Claudication	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0010 affected125 at risk
Intervertebral Disc Compression	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Intestinal Ischaemia	Gastrointestinal disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Lung Neoplasm Malignant	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Malnutrition	Metabolism and nutrition disorders		Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Multi-Organ Failure	General disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Muscular Weakness	General disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Myocardial Infarction	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0005 affected127 at risk EG0016 affected125 at risk
Odema Peripheral	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Osteoarthritis	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Osteoporotic Fracture	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Peripheral Embolism	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Peripheral Ischaemia	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Pneumonia	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0002 affected127 at risk EG0014 affected125 at risk
Polymyalgia Rheumatica	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Pulmonary Odema	General disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Pyelonephritis	Renal and urinary disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Pyrexia	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Renal Failure	Renal and urinary disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0012 affected125 at risk
Respiratory Tract Infection Viral	Respiratory, thoracic and mediastinal disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Rib Fracture	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Right Ventricular Failure	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Septic Shock	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Sick Sinus Syndrome	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Sepsis	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Spinal Column Stenosis	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Spinal Fracture	Musculoskeletal and connective tissue disorders	MedDRA 10.0	Systematic Assessment	EG0001 affected127 at risk EG0010 affected125 at risk
Syncope	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0003 affected127 at risk EG0011 affected125 at risk
Therapeutic Agent Toxicity	Injury, poisoning and procedural complications	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Transient Ischaemic Attack	Nervous system disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Urosepis	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Venous Thrombosis Limb	Vascular disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Ventricular Tachycardia	Cardiac disorders	MedDRA 10.0	Systematic Assessment	EG0002 affected127 at risk EG0011 affected125 at risk
Vertigo	General disorders	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk
Herpes Zoster	Infections and infestations	MedDRA 10.0	Systematic Assessment	EG0000 affected127 at risk EG0011 affected125 at risk

ID	Term
D006333	Heart Failure
D018487	Ventricular Dysfunction, Left
D018754	Ventricular Dysfunction

ID	Term
D002216	Captopril
D004656	Enalapril
D017706	Lisinopril
D017257	Ramipril
C052035	trandolapril
D017298	Bisoprolol
D000077261	Carvedilol
D008790	Metoprolol
C081643	candesartan
C077793	candesartan cilexetil
D000068756	Valsartan
D000077545	Eplerenone
D013148	Spironolactone
D004232	Diuretics
D001800	Blood Specimen Collection

Ancestor Terms

ID	Term
D011392	Proline
D007098	Imino Acids
D000598	Amino Acids, Cyclic
D000596	Amino Acids
D000602	Amino Acids, Peptides, and Proteins
D004151	Dipeptides
D009842	Oligopeptides
D010455	Peptides
D006574	Heterocyclic Compounds, 2-Ring
D000072471	Heterocyclic Compounds, Fused-Ring
D006571	Heterocyclic Compounds
D050198	Phenoxypropanolamines
D011412	Propanolamines
D000605	Amino Alcohols
D000438	Alcohols
D009930	Organic Chemicals
D020005	Propanols
D000588	Amines
D002227	Carbazoles
D007211	Indoles
D006575	Heterocyclic Compounds, 3-Ring
D013777	Tetrazoles
D001393	Azoles
D006573	Heterocyclic Compounds, 1-Ring
D014633	Valine
D000597	Amino Acids, Branched-Chain
D000601	Amino Acids, Essential
D007783	Lactones
D011283	Pregnenes
D011278	Pregnanes
D013256	Steroids
D000072473	Fused-Ring Compounds
D011083	Polycyclic Compounds
D045283	Natriuretic Agents
D045505	Physiological Effects of Drugs
D020228	Pharmacologic Actions
D020164	Chemical Actions and Uses
D013048	Specimen Handling
D019411	Clinical Laboratory Techniques
D019937	Diagnostic Techniques and Procedures
D003933	Diagnosis
D011677	Punctures
D013514	Surgical Procedures, Operative
D008919	Investigative Techniques

ID	Term
D006331	Heart Diseases
D002318	Cardiovascular Diseases

ID	Type	Description	Link
EUDRACT No. 2006-001259-36
SIGNAL HF